Giannis Antetokounmpo joins Prenetics (NASDAQ: PRE) as IM8 partner and shareholder
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Prenetics Global Limited announced a multi-year global partnership with NBA champion and two-time MVP Giannis Antetokounmpo, who becomes a global partner of IM8 and a shareholder in Prenetics. This aligns his 35 million-plus social followers with IM8’s growth strategy across the United States, Europe, Africa, and Asia.
IM8, co-founded with David Beckham, has rapidly scaled since its December 2024 launch, reaching $100 million in annualized recurring revenue in 11 months, more than 22 million servings delivered and about 750,000 customer purchases in 31 countries. The brand is projected to generate approximately $180–$200 million in revenue in 2026.
Management highlights strong alignment with athlete-partners, all of whom hold equity, and notes up to $42.75 million in combined corporate and personal share commitments. Prenetics reports approximately $160 million of adjusted liquidity and zero debt as of March 1, 2026, with adjusted EBITDA profitability targeted by Q4 2027.
Positive
- Rapid IM8 growth and revenue outlook: IM8 reached $100 million in annualized recurring revenue within 11 months and is projected to generate approximately $180–$200 million in revenue in 2026, signaling strong early traction in the premium nutrition category.
- Strong liquidity and no debt: Prenetics reports approximately $160 million of total adjusted liquidity and zero debt as of March 1, 2026, supporting continued investment in IM8’s global expansion while targeting adjusted EBITDA profitability by Q4 2027.
Negative
- None.
Insights
High-profile equity partnership supports IM8 growth with strong balance sheet.
Prenetics is tying its IM8 expansion to star athlete equity partners, adding Giannis Antetokounmpo as a shareholder and global partner. This builds on existing relationships with David Beckham, Aryna Sabalenka and Ollie Bearman, emphasizing long-term alignment rather than one-off endorsements.
IM8’s scale-up has been unusually rapid, with $100 million in annualized recurring revenue reached in 11 months and projected IM8 revenue of $180–$200 million in 2026. Management also cites up to $42.75 million in combined corporate and executive share commitments.
The company reports total adjusted liquidity of about $160 million and zero debt as of March 1, 2026, while targeting adjusted EBITDA profitability by Q4 2027. Future disclosures on whether IM8 revenue and margin trends track these projections will help clarify the long-term earnings profile.
Key Figures
IM8 annualized recurring revenue: $100 million
IM8 2026 revenue projection: $180–$200 million
Total adjusted liquidity: approximately $160 million
+5 more
8 metrics
IM8 annualized recurring revenue
$100 million
Reached within 11 months of IM8 launch in December 2024
IM8 2026 revenue projection
$180–$200 million
Projected full-year IM8 revenue for 2026
Total adjusted liquidity
approximately $160 million
As of March 1, 2026, on a zero-debt basis
Cash and cash equivalents
$93.0 million
Component of adjusted liquidity as defined by Prenetics
Financial assets at fair value
approximately $29.3 million
Primarily fixed income funds within adjusted liquidity
Digital asset holdings
approximately $34.2 million
Included in total adjusted liquidity
Escrowed sale proceeds
$7.3 million
$6.3 million ACT Genomics and $1.0 million Insighta in escrow
Share-related commitments
up to $42.75 million
Includes up to $40 million buyback and $2.75 million executive purchases
Key Terms
annualized recurring revenue, adjusted liquidity, NSF Certified for Sport, randomized controlled trial, +2 more
6 terms
annualized recurring revenue financial
"IM8 reached $100 million in annualized recurring revenue within just 11 months"
Annualized recurring revenue is the predictable income a business expects to earn over a year from ongoing customer subscriptions or contracts. It’s similar to estimating how much money you would make in a year if your current monthly income stayed the same. Investors use this figure to assess the stability and growth potential of a company's revenue stream.
adjusted liquidity financial
"The Company’s total adjusted liquidity1 stands at approximately $160 million"
Adjusted liquidity is a measure of how much readily available cash and near-cash assets a business has after excluding items that aren’t truly usable—like restricted cash, one-time receipts, or temporary borrowings. It tells investors the realistic cushion a company has to pay bills, invest, or survive a downturn, similar to checking how much spendable money you have in your wallet after accounting for reserved funds and upcoming automatic payments.
NSF Certified for Sport technical
"IM8’s formulations are NSF Certified for Sport and backed by a 12-week randomized controlled trial"
NSF Certified for Sport is a third-party safety seal showing a supplement or sports product has been independently tested to be free of banned substances, contaminants and undeclared ingredients, and that it was made under quality controls. For investors, this label matters because it lowers the chance of regulatory action, athlete bans, or recalls and typically boosts consumer trust and sales—think of it as a safety inspection sticker that helps a product sell more reliably in a sensitive market.
randomized controlled trial technical
"backed by a 12-week randomized controlled trial conducted by the San Francisco Research Institute"
A randomized controlled trial is a research method that tests the effects of a new idea or treatment by randomly dividing participants into two groups: one that receives the treatment and one that does not. This approach helps ensure that the results are fair and unbiased, providing clear evidence about whether the treatment actually works. Investors value such trials because they offer reliable information that can influence decision-making and reduce uncertainty.
adjusted EBITDA financial
"with adjusted EBITDA profitability targeted by Q4 2027"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
digital asset holdings financial
"digital asset holdings valued at approximately $34.2 million"
Digital asset holdings are the collection of electronically recorded assets someone or a company owns—such as cryptocurrencies, tokenized securities, or other digital representations of value—kept in digital wallets or on distributed ledgers. Investors care because these holdings affect a firm's reported value, liquidity and risk profile: they can swing in price quickly, require special custody and security, and face different regulatory rules than traditional cash or stocks, much like owning cash in a foreign currency or a collection of rare trading cards.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Commission File Number 001-41401
Prenetics Global Limited
Unit 703-706, K11 Atelier 728 King’s Road, Quarry Bay Hong Kong | |||||
(Addresses of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
On April 2, 2026, Prenetics Global Limited (the “Company”) issued a press release announcing a multi-year global partnership with Giannis Antetokounmpo. A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.
EXHIBIT INDEX
| Exhibit no. | Description | |||||||
| 99.1 | Press Release - Prenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Prenetics Global Limited | ||||||||
| By: | /s/ Lo Hoi Chun | |||||||
| Name: | Lo Hoi Chun | |||||||
| Title: | Chief Financial Officer | |||||||
| Date: April 2, 2026 | ||||||||
Prenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership
Giannis becomes the first NBA athlete shareholder in a NASDAQ-listed health and longevity brand, joining the fastest supplement company ever to reach $100M ARR in just 11 months
Giannis unlocks 35 million followers across social channels - NBA broadcasted in 215 countries
To learn more about Giannis and IM8, please visit www.im8health.com
NEW YORK, N.Y., April 2, 2026 — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced a multi-year global partnership with NBA Champion and two-time MVP Giannis Antetokounmpo. Giannis becomes a Global Partner of IM8 and the first NBA athlete shareholder in a NASDAQ-listed health and longevity brand in Prenetics, demonstrating his undeniable long-term support for the company.
The partnership unites one of the most dominant and beloved athletes in professional sports with the fastest-growing supplement brand ever recorded. Since launching in December 2024, IM8 reached $100 million in annualized recurring revenue within just 11 months, a pace unprecedented in the supplement industry. Today, IM8 has delivered more than 22 million servings, and reached more than 750,000 customer purchases across 31 countries, and is projected to generate approximately $180 million to $200 million in full year revenue in 2026.
Antetokounmpo commands over 35 million followers across his social platforms, including Instagram, X, and TikTok, with particular strength in the United States, Europe, Africa, and Asia, geographies that align
directly with IM8’s global expansion roadmap. The NBA is broadcast in over 215 countries and territories, providing IM8 with a direct channel into markets the brand has not yet activated at scale.
Danny Yeung, CEO of Prenetics and co-founder of IM8, commented, “David Beckham co-founded IM8. Aryna Sabalenka and Ollie Bearman took equity. And now Giannis — because he represents everything IM8 stands for: relentless discipline, authenticity, and an unwillingness to cut corners. The fact he chose 100% equity over any cash compensation says more about his belief in what we’re building than any marketing campaign ever could. He's not lending us his name. He's investing in our future.”
Danny added “Four sports. Four of the most respected athletes on the planet. More than 200 million followers combined. Every one of them chose to become a shareholder. No other brand in this industry has that – and with approximately $160 million in liquidity, zero debt, and a clear path to profitability, we have the roster and the capital to match the conviction. We’re building a generational brand in consumer health, and rewarding every shareholder and partner building it with us.”
Giannis Antetokounmpo said “I’m very careful about what I put in my body and what I put my name on. For me, taking care of my body isn’t just about basketball — it’s about how I live every day. When I started taking IM8, I noticed the difference and it quickly became part of my daily routine. It’s something that helps support my energy, recovery, and overall health so I can be at my best, both on and off the court. As I kept using it, I wanted to learn more about the people behind it. I spent time getting to know the team and saw how serious they are about the science, the ingredients, and building something real in health and performance. That’s what made me want to be part of what they’re building and support the brand as a shareholder.”
Why This Partnership Matters
For Prenetics shareholders, the Antetokounmpo partnership addresses three strategic priorities.
First, it expands IM8’s addressable market. Antetokounmpo’s core audience skews 18–34, a demographic where IM8 is currently under-scaled. The NBA is broadcast in over 215 countries and territories. This partnership gives IM8 a direct channel into markets the brand has not yet activated at scale, at a time when the Company is targeting $180 million to $200 million in IM8 revenue for fiscal year 2026.
Second, it deepens IM8’s cross-sport credibility. Football, Tennis, Formula 1, and now Basketball. Four sports. Four equity holders. No other supplement brand has assembled a roster of this caliber, or this structure. For consumers, it answers the question of product quality before it is asked.
Third, it reinforces structural alignment between the Company and its partners. When Antetokounmpo joins as a shareholder, he is making the same bet Prenetics management has made with up to $42.75 million in combined corporate and personal share commitments, including the up to $40 million share repurchase program and $2.75 million in recent executive open-market purchases. The Company’s total adjusted liquidity1 stands at approximately $160 million on a zero-debt basis as of March 1, 2026, with adjusted EBITDA profitability targeted by Q4 2027.
IM8: The Product Behind the Conviction
1 Adjusted liquidity is a non-IFRS financial measure, comprising: cash and cash equivalents of $93.0 million, financial assets at fair value through profit or loss (primarily comprising of fixed income funds) of approximately $29.3 million based on the most recent available valuation and subject to finalization as part of the ongoing annual audit, digital asset holdings valued at approximately $34.2 million, and portions of gross proceeds of the ACT Genomics sale and Insighta sale transactions held in escrow pending fulfillment of customary release conditions of $6.3 million and $1.0 million, respectively. Our total adjusted liquidity decreased from approximately $171 million as of February 15, 2026 to approximately $164 million as of March 1, 2026 on account of expenses used to support inventory growth and marketing costs on advertising services.
IM8’s flagship product, Daily Ultimate Essentials PRO, delivers 90 premium ingredients at clinical doses in a single daily serving. The brand’s second pillar, Daily Ultimate Longevity, targets the 12 hallmarks of aging with 10 key compounds, offering a science-backed approach to cellular health and healthy aging. Both products can be combined as the Beckham Stack, a complete daily protocol.
IM8’s formulations are NSF Certified for Sport and backed by a 12-week randomized controlled trial conducted by the San Francisco Research Institute, with results showing significant improvements across energy, digestion, sleep, and focus. The Company expects to initiate multiple new clinical trials in 2026, with results anticipated by year-end.
For Giannis media files, please find it here: https://im8health.com/pages/press
For Giannis media files, please find it here: https://im8health.com/pages/press
About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company’s flagship consumer brand, IM8, co-founded with David Beckham and trusted by NBA superstar, Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka and F1 phenom Ollie Bearman, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, achieving an impressive milestone of surpassing $100 million in annualized recurring revenue within just 11 months of operations, and is now sold in more than 30 countries worldwide.
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.
About Giannis Antetokounmpo
Antetokounmpo’s journey from Sepolia, Athens to NBA Champion is one of the most compelling stories in professional sports. The son of Nigerian immigrants who sold goods on the streets of Athens to support his family, Giannis built his career on discipline, authenticity, and an extraordinary work ethic. He has earned two NBA MVP awards (2019, 2020), an NBA Championship and Finals MVP (2021), Defensive Player of the Year (2020), NBA Cup MVP (2024), and was named to the NBA 75th Anniversary Team.
Investor Relations Contact
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance reflects management’s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company’s purchase of digital asset subjects it to risks related to extreme volatility and speculative nature of digital asset; the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers’ expectations; the Company’s ability to further develop and grow its business, including new products and services; and its ability to identify and execute on M&A opportunities. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
FAQ
What partnership did Prenetics (PRE) announce with Giannis Antetokounmpo?
Prenetics announced a multi-year global partnership making Giannis Antetokounmpo a Global Partner of IM8 and a shareholder in Prenetics. The collaboration combines his global profile with IM8’s premium health and longevity products to support brand expansion across key international markets.
How fast is Prenetics’ IM8 brand growing according to the 6-K?
IM8 reached $100 million in annualized recurring revenue within just 11 months of launching in December 2024. The brand has delivered more than 22 million servings and around 750,000 customer purchases across 31 countries, illustrating rapid adoption in the consumer health space.
What revenue does Prenetics (PRE) project for IM8 in 2026?
Prenetics projects IM8 will generate approximately $180 million to $200 million in full-year revenue in 2026. This outlook reflects continued global rollout of its flagship products and strategic partnerships with high-profile athlete shareholders across multiple sports.
What is Prenetics’ liquidity position and debt level?
Prenetics reports total adjusted liquidity of approximately $160 million on a zero-debt basis as of March 1, 2026. Adjusted liquidity includes cash, financial assets, digital assets and escrowed sale proceeds, providing financial flexibility to fund inventory, marketing and broader IM8 growth initiatives.
When does Prenetics aim to achieve adjusted EBITDA profitability?
Prenetics is targeting adjusted EBITDA profitability by the fourth quarter of 2027. This goal is supported by IM8’s rapid revenue growth, expanding global customer base, and a strong liquidity position that allows ongoing investment in products, clinical trials and marketing capabilities.